Vol 49, No 2 (2018)
SHORT COMMUNICATION
Published online: 2018-08-30

open access

Page views 291
Article views/downloads 282
Get Citation

Connect on Social Media

Connect on Social Media

Przewlekłe leczenie przeciwkrzepliwe

Krystyna Zawilska1
DOI: 10.2478/ahp-2018-0009
Acta Haematol Pol 2018;49(2):47-49.

Abstract

Unprovoked venous thromboembolism (VTE) - proximal venous thrombosis or pulmonary embolism - should be treated either 3 months or indefinitely if the risk of bleeding is low. This article summarizes the efficacy and safety of extended therapy of VTE with direct oral anticoagulants (DOAC) in comparison with warfarin, as well as the role of of acetylsalicylic acid (ASA) for the long-term prevention of recurrent VTE. As the Survet study showed, for some patients who have already completed at least 6 months of anticoagulant treatment for their index VTE event, an oral glycosaminoglycan - sulodexide associated with compression therapy is a good choice, because it decreases the incidence of recurrences of VTE without detectable risks for the patients’ safety.

Article available in PDF format

View PDF (Polish) Download PDF file